Summary
Bristol Myers Squibb (BMY) reported its financial results for the second quarter ended June 29, 2021, demonstrating continued execution on its strategic priorities. The company achieved significant revenue growth, driven by its key products, and maintained a strong financial position. Investors should note the company's progress in advancing its pipeline and its commitment to returning value to shareholders through share repurchases and dividends, balanced with ongoing investments in research and development.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $11.70B |
| Cost of Revenue | $2.45B |
| Gross Profit | $9.25B |
| R&D Expenses | $2.48B |
| SG&A Expenses | $1.88B |
| Operating Expenses | $10.15B |
| Interest Expense | $330.00M |
| Net Income | $1.05B |
| EPS (Basic) | $0.47 |
| EPS (Diluted) | $0.47 |
| Shares Outstanding (Basic) | 2.23B |
| Shares Outstanding (Diluted) | 2.25B |
Key Highlights
- 1Revenue increased compared to the prior year period, primarily driven by strong performance in key therapeutic areas and products.
- 2The company maintained a solid cash flow from operations, indicating efficient business management and the ability to fund ongoing initiatives.
- 3Significant investments in Research and Development (R&D) were made, underscoring BMY's commitment to innovation and future growth through pipeline advancement.
- 4The company continued its share repurchase program, demonstrating confidence in its valuation and a commitment to returning capital to shareholders.
- 5Net income and earnings per share (EPS) showed a positive trend, reflecting effective cost management and revenue growth.
- 6BMY highlighted progress in clinical trials and regulatory submissions for its pipeline assets, suggesting potential future revenue streams.
Frequently Asked Questions
Revenue growth was primarily driven by the strong performance of BMY's key in-line products, particularly within the hematology and oncology segments, as well as continued uptake of recently launched products.
Significant R&D investments are crucial for BMY's long-term strategy. While these investments represent an outflow, they are vital for developing new therapies and advancing the pipeline, which is expected to drive future revenue and profitability.
Bristol Myers Squibb continued its share repurchase program and maintained its dividend payments, reflecting a balanced approach to capital allocation that includes reinvesting in the business and providing returns to shareholders.
The filing acknowledges ongoing legal proceedings and updates the risk factors section. Investors should refer to Item 1 (Legal Proceedings) and Item 1A (Risk Factors) for detailed information on potential impacts to the company's operations and financial condition.